A Randomized, Double-Blind Comparative Trial Evaluating the Safety of Liposomal Amphotericin B versus Amphotericin B Lipid Complex in the Empirical Treatment of Febrile Neutropenia

R. Wingard, John; H. White, Mary; Anaissie, E.; Raffalli, John; Goodman, Joseph; Arrieta, Antonio; Amph/ABLC Collaborative Study Group, L

doi:10.1086/317451

Public

A Randomized, Double-Blind Comparative Trial Evaluating the Safety of Liposomal Amphotericin B versus Amphotericin B Lipid Complex in the Empirical Treatment of Febrile Neutropenia

Published in Clinical Infectious Diseases • Nov 15, 2000

Authors:

John R. Wingard

Mary H. White

E. Anaissie

Abstract

In this double-blind study to compare safety of 2 lipid formulations of amphotericin B, neutropenic patients with unresolved fever after 3 days of antibacterial therapy were randomized (1:1:1) to receive amphotericin B lipid complex (ABLC) at a dose of 5 mg/kg/d (n=78), liposomal amphotericin B (L A...

Subject

Chills

Medicine

Amphotericin B

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!